APA (7th ed.) Citation

Dang, N. H., Ogura, M., Castaigne, S., Fayad, L. E., Jerkeman, M., Radford, J., . . . Ando, K. (2018). Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma. British Journal of Haematology, 182(4), 583-586. https://doi.org/10.1111/bjh.14820

Chicago Style (17th ed.) Citation

Dang, Nam H., et al. "Randomized, Phase 3 Trial of Inotuzumab Ozogamicin Plus Rituximab Versus Chemotherapy Plus Rituximab for Relapsed/refractory Aggressive B‐cell Non‐Hodgkin Lymphoma." British Journal of Haematology 182, no. 4 (2018): 583-586. https://doi.org/10.1111/bjh.14820.

MLA (9th ed.) Citation

Dang, Nam H., et al. "Randomized, Phase 3 Trial of Inotuzumab Ozogamicin Plus Rituximab Versus Chemotherapy Plus Rituximab for Relapsed/refractory Aggressive B‐cell Non‐Hodgkin Lymphoma." British Journal of Haematology, vol. 182, no. 4, 2018, pp. 583-586, https://doi.org/10.1111/bjh.14820.